Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

Autor: Channing J. Der, Adrienne D. Cox, Autumn J. McRee, Christine Sers, Emanuel F. Petricoin, Kris C. Wood, Mareen Lüthen, Natalie Bublitz, Andrew P. Beelen, Jessica A. Sorrentino, Mariaelena Pierobon, Valerie Calvert, Elisa Baldelli, Irem Ozkan-Dagliyan, Amber M. Amparo, Runying Yang, Bjoern Papke, Kristina Drizyte-Miller, Clint A. Stalnecker, Kirsten L. Bryant, Sehrish Javaid, Jennifer E. Klomp, Andrew M. Waters, Craig M. Goodwin

Figure S7 page2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0acddd6baeccef281cd7c89ad06c366e
https://doi.org/10.1158/0008-5472.22432947

Data from Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

Autor: Channing J. Der, Adrienne D. Cox, Autumn J. McRee, Christine Sers, Emanuel F. Petricoin, Kris C. Wood, Mareen Lüthen, Natalie Bublitz, Andrew P. Beelen, Jessica A. Sorrentino, Mariaelena Pierobon, Valerie Calvert, Elisa Baldelli, Irem Ozkan-Dagliyan, Amber M. Amparo, Runying Yang, Bjoern Papke, Kristina Drizyte-Miller, Clint A. Stalnecker, Kirsten L. Bryant, Sehrish Javaid, Jennifer E. Klomp, Andrew M. Waters, Craig M. Goodwin

Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key genetic step that complements activation of KRAS in promoting the development and malignant growth of pancreatic ductal adenocarcinoma (PDAC). However, pharmacologic res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9aac2b4a73c2414e8aceef7834205187
https://doi.org/10.1158/0008-5472.c.6514275.v1

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant

Autor: Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G.E. de Vries, Andor W.J.M. Glaudemans, Philippe Aftimos, Géraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, 29(11), 2075-2084. American Association for Cancer Research Inc.
Iqbal, R, Yaqub, M, Bektas, H O, Oprea-Lager, D E, de Vries, E G E, Glaudemans, A W J M, Aftimos, P, Gebhart, G, Beelen, A P, Schuit, R C, Windhorst, A D, Boellaard, R & Menke-van der Houven van Oordt, C W 2023, ' 18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 29, no. 11, pp. 2075-2084 . https://doi.org/10.1158/1078-0432.CCR-22-2720
Iqbal, R, Yaqub, M, Bektas, H O, Oprea-Lager, D E, de Vries, E G E, Glaudemans, A W J M, Aftimos, P, Gebhart, G, Beelen, A P, Schuit, R C, Windhorst, A D, Boellaard, R & Menke-van der Houven van Oordt, C W 2023, ' [ 18 F]FDG and [ 18 F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ERþ Breast Cancer Undergoing Treatment with Rintodestrant ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 29, no. 11, pp. 2075-2084 . https://doi.org/10.1158/1078-0432.CCR-22-2720

Purpose: PET with 16α-[18F]-fluoro-17β-estradiol ([18F]FES) allows assessment of whole body estrogen receptor (ER) expression. The aim of this study was to investigate [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]FES PET/CT imaging for response pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::788412708fb95c56c2d56aa680859b89
https://research.rug.nl/en/publications/8e32bae8-23fb-49a6-8736-870f05c53bdf

Abstract 4204: CDK4/6 inhibition mitigates chemotherapy-induced immunosuppression and enhances the efficacy of chemo- immunotherapy in small cell lung cancer models

Autor: Thiruvengadam Arumugam, Irene G. Muñoz, Alissa Poteete, Fahoa Zhang, Monique Nilsson, John S. Yi, Jessica A. Sorrentino, Andrew P. Beelen, John V. Heymach

Publikováno v: Cancer Research. 82:4204-4204

Small cell lung cancer (SCLC) is an aggressive form of lung cancer with a notably low survival rate. Chemotherapy and more recently its combination with immunotherapy are the standard of care for extensive stage SCLC. Although this combinatorial trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46658aeb3915813c64049e0f21ae579c
https://doi.org/10.1158/1538-7445.am2022-4204

278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients

Autor: R Roylance, B. Krastev, Wenli Tao, Richard D. Baird, M. Maglakelidze, H-T. Arkenau, A. Crijanovschi, Jessica A. Sorrentino, C. Murias, I. Bulat, Ruhi Rai, Andrew P. Beelen, Andrew M Wardley, M. Gogiladze

Publikováno v: Annals of Oncology. 31:S351-S352

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5122265f68d5a8eb7ef03b44a2592ee5
https://doi.org/10.1016/j.annonc.2020.08.380